Eurofins Viracor Launches Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients
Eurofins Viracor ExPeCT CAR-T qPCR assay is a tool designed for monitoring and optimizating CAR-T therapies.
Eurofins Viracor, a Eurofins company specializing in testing for infectious diseases, immunology, and allergy, launched in February 2023 its Viracor ExPeCT chimeric antigen receptor T-cell (CAR-T) multiplexed quantitative real-time polymerase chain reaction (qPCR) assay. The tool is designed to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.
According to a press release from Feb. 16, 2023, the test is designed to provide clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient’s body, in turn offering potential insights into therapy effectiveness and what future treatment options may be advisable.
Source: Eurofins
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
